NasdaqCM - Delayed Quote USD

Chemomab Therapeutics Ltd. (CMMB)

0.6700 0.0000 (0.00%)
At close: April 24 at 4:00 PM EDT
0.6443 -0.03 (-3.84%)
After hours: April 24 at 7:47 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Adi Mor George Ph.D. Co-Founder, Chief Scientific Officer, CEO & Executive Director 330k -- 1982
Ms. Sigal Fattal CPA, M.B.A. Chief Financial Officer 322k -- 1971
Dr. Matthew B. Frankel M.B.A., M.D. Chief Medical Officer & VP of Drug Development 850k -- 1969
Barbara Lindheim Consulting Vice President of Investor & Public Relations, Strategic Communications -- -- --

Chemomab Therapeutics Ltd.

Building 7
Kiryat Atidim
Tel Aviv, 6158002
Israel
972 77 331 0156 https://www.chemomab.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Corporate Governance

Chemomab Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 28, 2024
    20-F: Periodic Financial Reports
    See Full Filing
  • Mar 07, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Jan 03, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Nov 15, 2023
    SC 13D/A: Tender Offer/Acquisition Reports
    See Full Filing
  • Nov 01, 2023
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing

Upcoming Events

May 09, 2024
Chemomab Therapeutics Ltd. Earnings Call

Related Tickers

CYCC Cyclacel Pharmaceuticals, Inc.
2.2999
+28.49%
 
APRE Aprea Therapeutics, Inc.
5.17
-2.82%
 
BPTS Biophytis S.A.
9.70
-4.78%
 
VRPX Virpax Pharmaceuticals, Inc.
3.1700
+0.63%
 
DNTH Dianthus Therapeutics, Inc.
21.32
-8.97%
 
VYNE VYNE Therapeutics Inc.
2.5700
+10.78%
 
PBM Psyence Biomedical Ltd.
0.7980
+5.00%
 
THAR Tharimmune, Inc.
0.3720
-1.85%
 
LXEO Lexeo Therapeutics, Inc.
12.50
+2.97%
 
LIXT Lixte Biotechnology Holdings, Inc.
3.2800
-4.65%